

# Residual Infusion Performance Evaluation (RIPE): A Single-Center Evaluation of Residual Volume Post-Intravenous Eravacycline Infusion

Alysa Baumann, PharmD, MBA, 340B ACE<sup>1</sup>; Kerry O. Cleveland, MD<sup>2</sup>; Michael S. Gelfand, MD<sup>2</sup>; Angela D. Covington, PharmD, MBA, BCPS, 340B ACE<sup>3</sup>; Nicholson B. Perkins III, PharmD<sup>4</sup>; Athena L.V. Hobbs, PharmD, BCIDP<sup>5</sup>

<sup>1</sup> Pharmaceutical Services, St. Jude Children's Research Hospital – Memphis, TN; <sup>2</sup> Division of Infectious Diseases University of Tennessee Health and Science Center – Memphis, TN; <sup>3</sup> Department of Pharmacy, Methodist University Hospital – Memphis, TN; <sup>4</sup> Pharmaceutical Sciences, University of Tennessee Health and Science Center – Memphis, TN; <sup>5</sup> Cardinal Health Innovative Delivery Solutions – Stafford, TX

## Background

- Infusion Nursing Society (INS) Standard of Practice notes there is a significant potential medication loss (up to 35%) with 50- and 100-mL solutions due to residual volume in the administration set<sup>1</sup>
- Institute for Safe Medication Practices (ISMP) recommends using microbore tubing and flushing the tubing after drug administration to minimize residual volume
- Overfill volume varies depending on manufacturer and bag size
  - 250 mL normal saline will have between 15-35 mL of overfill<sup>2</sup>
  - Overfill can be inconsistent even from the same manufacturer
- Data about residual volume for infusion volumes more than 100 mL is absent in published literature

## Purpose

- Compare residual antibiotic volume remaining in bag following intravenous (IV) infusion of eravacycline before and after implementation of interventions

## Methods

Patients receiving IV eravacycline at Methodist University Hospital	
<b>Study Design</b>	Quasi-experimental, descriptive, single-center
<b>Study Period</b>	Pre-intervention: July 1 – 31, 2021 Intervention: August 1 – October 31, 2021 Post-intervention: November 1 – 30, 2021
<b>Inclusion Criteria</b>	<ul style="list-style-type: none"> <li>• ≥18 years of age</li> <li>• Received at least one dose of IV eravacycline</li> </ul>
<b>Exclusion Criteria</b>	<ul style="list-style-type: none"> <li>• Active COVID-19 infection</li> <li>• Pregnancy</li> </ul>
<b>Facility Practices</b>	<ul style="list-style-type: none"> <li>• 297 cm standard bore tubing, holding up to 20 mL</li> <li>• Simple admixture<sup>3</sup></li> </ul>


<sup>3</sup> Drug added to diluent bag without concern for overfill

## Demographics

Characteristic	N = 16
<b>Mean Age ± SD (range), years</b>	58.1 ± 15.8 (27-86)
<b>Male, n (%)</b>	11 (68.8)
<b>Race</b>	
African American, n (%)	12 (75)
White, n (%)	3 (18.8)
Other, n (%)	1 (6.3)
<b>Mean Weight ± SD, kg</b>	87.9 ± 30.0
<b>Mean Serum Creatinine at Time of Drug Initiation ± SD, mg/dL</b>	1.8 ± 1.6

## Results

A total of 46 doses (n=9) were evaluated in the pre-intervention population compared to 21 doses (n=7) post-intervention.



Drug (mg) Evaluation	Amount of Drug in Residual Volume (mg)		Average Amount of Drug in Residual Volume (mg) ± SD	p value
	Minimum	Maximum		
<b>Pre-intervention (n = 46)</b>	1.63	40.46	13.53 ± 7.49	<0.0001
<b>Post-intervention (n = 21)</b>	0	20.9	4.69 ± 5.14	

## Results

A total of 46 doses (n=9) were evaluated in the pre-intervention population compared to 21 doses (n=7) post-intervention. The average amount of residual volume after a 250 mL infusion was 38.0 mL (~15% of total bag volume) for the pre-intervention group compared to 12.2 mL (<5% of total bag volume) for the post-intervention group (p<0.0001).

Volume Evaluation	Number of Doses		Average Volume Remaining (mL) ± SD	p value
	Day Shift	Night Shift		
<b>Pre-intervention (n = 46)</b>	22	24	38.04 ± 15.6	0.01
<b>Post-intervention (n = 21)</b>	11	10	12.2 ± 10.1	0.91
<b>Total ± SD</b>	33	34	25.14 ± 18.25	<0.0001

## Conclusion

- Approximately 15% of each dose was not infused during the pre-intervention compared to less than 5% in the post-intervention period
- Residual volume reflected an average of 13.53 mg of eravacycline remaining after infusion in the pre-intervention period compared to an average of 4.69 mg remaining in the post-intervention period
- Interventions included nursing education, order comments, and addition of diluent volume to the total volume to be infused on label
- Cost of discarded drug during pre-intervention period was \$893.45 compared to \$161.04 in the post-intervention period
- Subsequent research is required to determine the extrapolation of these results to outpatient infusion centers or other facilities

## References

1. Gorski LA, et al. 2021 infusion Therapy standards of Practice Updates. *Journal of Infusion Nursing*. 2021;44 (4):1-232. doi:10.1097/nan.0000000000000436.
2. Additional strategies to improve complete delivery of small-volume intermittent infusions. Institute For Safe Medication Practices. <https://www.ismp.org/resources/additional-strategies-improve-complete-delivery-small-volume-intermittent-infusions>. Published April 8, 2021.
3. Understanding and Managing IV Container Overfill. Institute For Safe Medication Practices. <https://www.ismp.org/resources/understanding-and-managing-iv-container-overfill>. Published November 14, 2013. Accessed April 27, 2022.

## Disclosures

The authors of this presentation do not have any disclosures concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.

